Today, Creyon Bio launched to develop oligonucleotide-based medicines for people living with common and rare diseases. Our Chief Scientific Officer Swagatam Mukhopadhyay dives deeper into our science. Learn more here: bit.ly/3hOFEZ6 #PrecisionMedicine #Biotech

Creyon Bio launched today! Creyon has a bold vision and big dreams. And to make big dreams a reality, you need a great team! Honored to be working with so many exceptional people and groups.

It’s been very hard keeping quiet for the last two years - thank you for your early and continued support in making our bold vision a reality.

.⁦Creyon Bio⁩ exits stealth to disrupt RNA drug dev. 2 years ago we backed one of the most exciting projects we have ever been a part of. Custom oligo based medicines, on demand, for diseases from ultra rare to common, via proprietary structural AI. cen.acs.org/business/start…

We were excited to talk with C&EN (Chemical & Engineering News) about our work to develop oligonucleotide-based medicines for people living with rare and common diseases. Read more: cen.acs.org/business/start… #AI #MachineLearning #Biotech

Thrilled to announce that David Dimmock has joined us Creyon Bio. He joins our amazing interdisciplinary team, grounding and connecting us deeply to the needs of the clinic. #oligonucleotide #PrecisionMedicine

Join our amazing team Creyon Bio. Come do great science, work closely and collaboratively with brilliant minds across multiple disciplines, and work on problems that will have a meaningful impact. Details - creyonbio.com/join-us/

We are pleased to announce David Fajgenbaum, MD, MD, MBA, as a Company Advisor & Board Observer. A leader in research & drug development, he will help Creyon connect with regulatory, patient, & clinical communities. Read more: creyonbio.com/latest-news/ #PrecisionMedicine #Biotech

Congratulations and thank you to the @CreyonBio teammates who completed this foundational work and shared the results of a novel approach in arXiv: arxiv.org/abs/2208.04976. #oglionucleotide #artificialintelligence #machinelearning

Grateful to share some of our latest research at Oligonucleotide Therapeutics Society. A small glimpse into our efforts at Creyon. Looking forward to sharing more of the brilliant work being done by the exceptional interdisciplinary Creyon team.

Thanks BIOS for such a good conversation about how Creyon Bio is learning the principles to engineer safe and efficacious Oligonucleotide-Based Medicines from idea through the clinic.

We're honored to share about our efforts to quickly develop precision medicines for rare and common diseases, whether for millions of patients or for just one, and to be included among so many other amazing DCVC and DCVC Bio portfolio companies. dcvc.com/reports/deep-t…

Baby Leo’s experience with #raredisease highlights the need for precision treatments. Grateful for our work with the TNPO2 Foundation. Read more about Leo's journey and how we engineered this particular investigational antisense oligonucleotide therapy. greaterlongisland.com/journey-of-hop…

Our CEO Chris Hart proposes a paradigm shift in how we approach oligonucleotide-based medicine development, emphasizing the need to understand the complex interplay between sequence and chemistry. Read more in Nucleic Acid Insights: insights.bio/nucleic-acid-i…

Please welcome Serge Messerlian DCVC, to our Board of Directors! With extensive leadership in life sciences, Serge brings valuable expertise to support our mission of reimagining drug development through AI-enabled engineering of OBMs. brnw.ch/21wMua9

We're officially welcoming Shaquille Vayda Lux Capital, to Creyon's Board of Directors! Shaq’s diverse experience spanning technology, aerospace and life sciences aligns well with our innovative approach to drug engineering. brnw.ch/21wMuaj

Our CEO Chris Hart is presenting at #MedInvest2024! Discover how we're engineering OBMs 100x more efficiently and learn about our AI-driven platform that's overcoming delivery challenges with targeted aptamers, transforming treatments for diseases. brnw.ch/21wMP2W

... and it begins.